Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - PLURISTEM THERAPEUTICS INC | exhibit_32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - PLURISTEM THERAPEUTICS INC | exhibit_31-2.htm |
| EX-32.2 - EXHIBIT 32.2 - PLURISTEM THERAPEUTICS INC | exhibit_32-2.htm |
| EX-23.1 - EXHIBIT 23.1 - PLURISTEM THERAPEUTICS INC | exhibit_23-1.htm |
| EX-31.1 - EXHIBIT 31.1 - PLURISTEM THERAPEUTICS INC | exhibit_31-1.htm |
| 10-K - 10-K - PLURISTEM THERAPEUTICS INC | zk1517290.htm |
Exhibit 10.32
[Translation from Hebrew]
State of Israel
Ministry of Economy
Industrial Research and Development Administration
Office of Chief Scientist
Jerusalem
Letter of Approval Number: 54516
(Fiscal regulation: 38300101)
Group: 13
To
Pluristem Ltd.
POB – 15105
Haifa 31905
Letter of Approval
|
1.
|
We hereby inform you that the research committee, by virtue of its authority according to Article 17 of the Law for the Encouragement of Research and Development in the Industry, 5744-1984 (hereinafter: the “R&D Law”), resolved in its meeting on 4/20/15 to approve the program as submitted by you on 12/15/2014, which subject matter is:
|
|
a.
|
Subject of approved program: Treatment with semi-mesenchyme placental cells grown in a 3D culture.
|
|
b.
|
Performing the approved program: Pluristem Ltd.
|
|
Registration Number: 513371666
(hereinafter - the “Approved Program”)
|
|
2.
|
a. The research and development expenses approved for the performance of the approved program will be in an amount of up to: NIS17,851,406.
In words: Seventeen million, eight hundred and fifty one thousand, four hundred and six NIS.
b. The rate of grant approved is 50% of the development expenses (addition with respect to a national priority zone A/ line of confrontation), which is up to an amount of NIS 8,925,703.
In words: Eight million, nine hundred and twenty five thousand, seven hundred and three NIS.
|
|
3.
|
The approval is conditioned upon fulfillment of the provisions of the law, regulations, rules and procedures promulgated thereunder and subject to the following terms:
|
|
a.
|
The approved program will be performed as detailed in your request within a period of 12 months – from 01/1/2015 and until 12/31/2015 (hereinafter: the “Performance Period”).
|
|
b.
|
(1) You must inform the Office of the Chief Scientist about every change in the control of the recipient of the grant in the company’s shares and/or in one of the following controlling means: (a) the right to vote in the company’s general meetings; (b) the right to appoint directors in the company; (c) the right to participate in the company’s profits.
(2) Transferring any percentage of the controlling means stated in subsection (1) to a non-Israeli resident or to a foreign company, which make the non-Israeli resident or foreign company an interested party as defined in the Securities Law, 5728-1968, requires notification to the Office of the Chief Scientist and a written undertaking of the non-Israeli resident or the foreign company to the R&D Law.
The letter of approval shall be signed in the form existing in the office of the Chief Scientist and in the website of the Ministry of Industry, Trade and Employment.
|
|
c.
|
Additional terms:
Royalties shall be paid on the company’s income.
|
|
d.
|
See the appendix in the matter of intellectual property.
|
|
e.
|
In the event of pledging the company’s assets to an Israeli bank against credit, the company must ensure that the pledge shall be subject to the R&D Law.
|
|
f.
|
If the program is connected to an agreement with an academic institution or an academic implementation company, the company must ensure that the agreement is subject to the provisions of the R&D Law.
|
|
Sincerely,
|
|
|
/s/ Avi Hason
|
|
|
Avi Hason
The Chief Scientist
|